| 5.05 1.34 (36.12%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.07 |
1-year : | 7.09 |
| Resists | First : | 5.19 |
Second : | 6.07 |
| Pivot price | 3.76 |
|||
| Supports | First : | 3.84 |
Second : | 3 |
| MAs | MA(5) : | 4.11 |
MA(20) : | 3.84 |
| MA(100) : | 3.93 |
MA(250) : | 4.04  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 62.9 |
D(3) : | 58.4 |
| RSI | RSI(14): 62.7 |
|||
| 52-week | High : | 9.25 | Low : | 1.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADIL ] has closed Bollinger Bands are 16.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.2 - 5.22 | 5.22 - 5.25 |
| Low: | 3.78 - 3.8 | 3.8 - 3.81 |
| Close: | 5.01 - 5.04 | 5.04 - 5.08 |
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Thu, 29 Oct 2026
Adial Pharmaceuticals, Inc. (ADIL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 28 Oct 2026
Adial Pharmaceuticals Announces Name Change to Azora - GlobeNewswire
Wed, 28 Oct 2026
symbol__ Stock Quote Price and Forecast - CNN
Tue, 27 Oct 2026
ADIAL PHARMACEUTICALS, INC. SEC Filing (Oct 27, 2026) - Stock Titan
Mon, 26 Oct 2026
A finance executive who helped raise over $1 billion is expected to lead Adial's finances if shareholders approve. - Stock Titan
Sat, 10 Oct 2026
Adial Pharmaceuticals (ADIL) Slips 1.76% to $3.90 as Shares Hold Above $3.70 Support - Synthetic Long - https://www.dars.gov.et/
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.11e+006 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 245 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.149e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.1 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.76 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -20.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.65 |
| Price to Cash Flow | -0.52 |
| Dividend | 0 |
| Forward Dividend | 183320 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|